4D Path
- Company typePrivate
- Founded2016
- HeadquartersBelmont, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
4D Path firmographics
Firmographics- Name
- 4D Path
- Legal name
- 4D Path Inc.
- Website
- https://4dpath.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
4D Path industry classification
Industry- Product category
- Computational Pathology & Predictive Oncology Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Software Publishers (5132)
- SIC
- Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where 4D Path is headquartered
LocationHeadquarters
- HQ city
- Belmont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
4D Path business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Biopharma biomarker discovery and development partnerships: Strategic collaborations with biopharmaceutical companies (e.g., Daiichi Sankyo for ADC program) to develop predictive biomarkers for specific therapeutic candidates — custom treatment prediction signatures developed per therapy of interest.
- Clinical trial biomarker analytics: Exploratory biomarker collaboration in prospective clinical trials (e.g., Phase II DAD-IO trial supported by Gilead) where QPOR analyzes pre-treatment biopsy slides to generate predictive biomarkers — revenue tied to clinical trial engagements.
- Strategic financing rounds (capital raises): Recurring private financing from strategic investors (e.g., 2026 first close of strategic financing; 2023 Form D exempt offering of approximately $16.97M; prior rounds totaling $6.4M as of December 2019) to fund platform development and clinical validation.
- Platform distribution via PathPresenter ClinPx: 4D Q-plasia OncoReader Breast distributed through PathPresenter's Clinical Workflow Platform ClinPx (currently for Research Use Only) — generates reach through 40,000+ global pathologist users.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based / partnership engagement for biopharma and clinical trial customers; QPOR Breast distributed via PathPresenter ClinPx (RUO). |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels7 records
4D Path product offering
Product offeringCore offering
4D Path develops and sells the Q-Plasia OncoReader (QPOR™) platform, a patented cloud-based AI software that converts digitized H&E-stained whole-slide biopsy and cytology images into predictive biomarkers of cancer therapy response by quantifying cell cycle deregulation and tumor immune microenvironment dynamics. The company sells its breast-cancer-specific 4D QPOR Breast product (FDA Breakthrough Device Designation) and develops customized treatment prediction signatures in partnership with biopharmaceutical companies, clinical research organizations, and academic cancer centers.
Product overview
4D Path offers a single unified, cloud-based AI platform — the patented Q-Plasia OncoReader (QPOR™) — under which it sells a beachhead product (4D QPOR Breast) and a growing portfolio of pan-cancer predictive biomarker signatures. The core QPOR™ engine ingests digitized H&E-stained biopsy and cytology whole-slide images, computes 29+ continuous-scale biological indices capturing cell-cycle deregulation and tumor immune-microenvironment dynamics, and outputs structured predictive biomarker reports. Layered on top of this core platform are productized offerings: 4D QPOR Breast (breast cancer, FDA Breakthrough Device Designation); the customized Treatment Prediction Signature (e.g., CmbINAC for germline BRCA HER2-negative breast cancer developed with TBCRC/DFCI); and a multi-indication portfolio of digital treatment-predictive biomarkers under development or in clinical trials for triple-negative breast cancer, bladder cancer, ovarian, lung, colorectal, melanoma, and additional ADC and immunotherapy programs.
Differentiator
Problem solved
Functional benefit
Brands
- QPOR (Q-Plasia OncoReader): Cloud-based, AI-driven, deterministic software platform that converts digitized H&E biopsy images into quantitative, physics-informed treatment predictive biomarkers measuring cell cycle deregulations and tumor immune microenvironment dynamics.
- 4D Q-Plasia OncoReader Breast (QPOR Breast)
Products and services
- Q-Plasia OncoReader (QPOR™) Platform Patented, cloud-based, fully automated AI software platform that converts digitized H&E whole-slide biopsy/resection and cytology images into biological signatures and predictive biomarkers by quantifying cell-cycle deregulation and tumor immune-microenvironment dynamics via statistical-physics-based analysis. Operates as an end-to-end image-to-report solution deployed on cloud infrastructure and integrated into existing PACS and digital pathology workflows. Sold to biopharmaceutical companies and clinical research organizations for biomarker co-development and clinical trial analytics.
- 4D Q-Plasia OncoReader Breast (4D QPOR Breast) Beachhead product of the QPOR platform focused on breast cancer. Provides an adjunct diagnostic tool for histopathologists to improve diagnostic accuracy of breast cancer features (invasiveness, grade, HER2 status, hormone receptor status, Ki67) solely from H&E biopsy/resection images. Currently distributed for Research Use Only via PathPresenter's ClinPx Clinical Workflow Platform.
- Customized Treatment Prediction Signature (e.g., CmbINAC) Custom-built predictive biomarker signature combining QPOR indices (e.g., IHI, PI, G1SI) to predict response to a specific therapy in a specific indication. Developed in collaboration with partners such as TBCRC and Dana-Farber Cancer Institute for biopharmaceutical clinical programs (e.g., ADC and neoadjuvant chemotherapy response).
Quantifiable outcome
- >80% accuracy using QPOR vs ~40% standard of care in TNBC neoadjuvant chemotherapy response prediction (N=88); up to 98% with customized screen, >100% increase in %Responder
- +5 more outcomes
Companies that use 4D Path
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
4D Path technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature8 records
4D Path partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, flagship and minor.
- Versiti Clinical Trials Services (VCTS)corePartnership to bring QPOR platform to pharmaceutical companies and CROs working with VCTS. VCTS clients immediately gain access to physics-inspired, AI-driven deterministic platform that transforms routine biopsy images into clear treatment predictive biomarkers. Strengthens VCTS's position as a leader in oncology clinical trials.
- Daiichi SankyoflagshipCollaboration to develop next-generation predictive biomarkers for an antibody drug conjugate (ADC) clinical development program. 4D Path will apply QPOR to standard H&E-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics to identify patients most likely to benefit from the select ADC. Approach compatible with both retrospective analyses of archived clinical specimens and prospective evaluation in ongoing and future studies.
- Dana-Farber Cancer Instituteflagship4D Path joined as exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences. 4D Path will apply its QPOR platform to analyze pre-treatment biopsy slides and generate predictive biomarkers for response to a novel combination therapy of Sacituzumab Govitecan + Enfortumab Vedotin +/- Pembrolizumab in patients with locally advanced/metastatic urothelial carcinoma.
- Gilead SciencesflagshipGilead Sciences supports the Phase II DAD-IO clinical trial in urothelial carcinoma (with Sacituzumab Govitecan, an ADC from Gilead). 4D Path serves as exploratory biomarker collaborator using QPOR to generate predictive biomarkers from pre-treatment biopsies.
- AMD and Oracle (Oracle Cloud Infrastructure)coreCollaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. QPOR platform runs natively on AMD EPYC CPUs on Oracle Cloud Infrastructure (OCI) to convert routine biopsy images into interpretable biomarkers of tumor and immune response. Achieves reproducibility, cost efficiency, scalability and regulatory-friendly insights for clinical trial execution.
- Translational Breast Cancer Research Consortium (TBCRC)flagshipLong-standing research collaboration with TBCRC and Dana-Farber Cancer Institute (DFCI) on Phase II breast cancer trials (TBCRC 030, TBCRC 031). QPOR has predicted neoadjuvant chemotherapy response in TNBC and HER2-/ER+ breast cancer with >80% accuracy vs ~40% standard of care; 9X increased response odds in paclitaxel arm (TBCRC 030 published in JNCI).
- Friends of Cancer ResearchminorCo-founder Dasgupta and Mukhopadhyay participated in a Friends of Cancer Research panel discussion on computational pathology in oncology drug development, contributing to a white paper on platform risk classification, transparency, and common reference standards.
- Leeds Teaching Hospitals NHS Trust (Innovation Pop-Up)coreFormal membership of Leeds Teaching Hospitals NHS Trust's Innovation Pop-Up, an international community of high-tech start-ups led by clinicians, scientists and entrepreneurs providing a test bed for new innovations before NHS implementation. Working with NHS Histopathology, University of Leeds, and University of Bradford to validate QPOR platform.
- Evident Scientific and Sakura Finetek USAminorCollaboration to present new study at the 2023 National Society for Histotechnology (NSH) Convention on automated robust image analysis qualifying H&E staining adequacy with varying hematoxylin and eosin incubation times. Aligns 4D Path's image analysis with microscopy/imaging and histopathology product leaders.
- PathPresentercoreGlobal partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter's ClinPx Clinical Workflow Platform. Pathologists can run 4D Q-Plasia OncoReader Breast directly within the ClinPx whole slide image viewer (scanner-agnostic). Product is for Research Use Only (RUO); not FDA or EMA approved for primary diagnosis.
- 4D Path Scientific Advisory Board (Dr. Craig Bunnell, Dr. Stuart Schnitt, Dr. Eric Winer, Dr. Puay Hoon Tan, Dr. Lee Schwartzberg)coreStrategic advisory group of internationally recognized oncology, pathology and translational research leaders from Dana-Farber, Yale Cancer Center, Renown Health/OneOncology, Luma Medical Centre Singapore (WHO Classification Board member) — provides clinical direction, validates scientific foundation, and supports pan-cancer expansion.
- University of LeedscoreExtended existing partnership through 2027 for collaborative validation of new technology to help doctors more accurately diagnose breast cancer. Successfully completed three breast cancer clinical studies at Leeds analyzing cases from over 1,000 patients across multiple trials; plans to expand trials to skin, lung, gynecological and head and neck cancers.
Scale indicators14 records
Recent moves6 records
Expansion highlights7 records
4D Path competitors and assessment
Company assessmentDirect peers
- Paige.AI: Paige builds AI-enabled digital pathology products for cancer diagnosis and has secured multiple FDA clearances (including the first FDA-authorized AI pathology product). It is the closest direct competitor to 4D Path in applying AI to H&E whole-slide images for oncology decision support.
- PathAI: PathAI provides AI-powered pathology platforms used by biopharma sponsors for biomarker discovery and by health systems for diagnostic decision support. Like 4D Path, it offers both companion-diagnostic-style biopharma analytics and clinical pathology AI, making it a directly comparable peer.
- Ibex Medical Analytics: Ibex develops AI-based cancer diagnostics for pathology, with deployments in clinical labs across multiple geographies for breast, prostate, and GI cancers. It is a direct peer in AI-driven H&E interpretation for oncology and competes for the same clinical and biopharma customers.
- Owkin: Owkin applies AI to pathology and multimodal patient data to discover biomarkers and predict treatment response for biopharma R&D. Its federated-learning approach to digital pathology and biopharma partnership model closely mirrors 4D Path's positioning with pharma sponsors.
- Proscia: Proscia offers a digital pathology platform with built-in AI applications for routine pathology workflows and biomarker quantification. It targets biopharma and clinical labs with H&E-centric AI tools, overlapping materially with QPOR's beachhead product positioning.
Broad incumbents
- SOPHiA GENETICS: SOPHiA GENETICS operates a broader AI-driven genomic and multimodal analytics platform used by hospitals and pharma, including Erin Feeney (4D Path's CCO) previously. It is comparable as a broader AI-diagnostics incumbent with oncology applications, though its core modality is genomics rather than H&E image-based biomarkers.
- Tempus Labs: Tempus is a large, well-capitalized precision medicine company combining molecular and imaging data (including pathology AI) with clinical data to serve biopharma and providers. It competes for the same biopharma biomarker budgets but across a much broader multi-omics portfolio.
- Roche (Ventana Digital Pathology): Roche's Ventana digital pathology business provides slide scanners, image management, and AI-augmented algorithms integrated into a global pathology ecosystem. It is an incumbent serving similar pathologist end users and biopharma partners, with portfolio scale that exceeds 4D Path's offering.
- Philips Digital Pathology: Philips offers the IntelliSite Digital Pathology platform (iSyntax format, supported by QPOR) along with AI-driven pathology applications. It is comparable as a broad incumbent scanner and workflow vendor reaching the same pathologist and clinical-trial customer base.
Emerging players
- Strata Oncology: Strata Oncology focuses on molecular profiling and precision oncology decision support, including treatment selection for advanced cancer patients. It overlaps with 4D Path on the precision oncology / companion-diagnostic axis but primarily uses molecular rather than H&E image-based biomarkers.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
4D Path social profiles
Digital presence4D Path compliance and trust
Trust signalCompliance5 records
4D Path financial estimates
Financial estimateRevenue estimate
Valuation estimate
4D Path leadership team
Management profileNumber of profiles
Profiles11 records
4D Path funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4D Path M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4D Path
What does 4D Path do?
4D Path develops and sells the Q-Plasia OncoReader (QPOR™) platform, a patented cloud-based AI software that converts digitized H&E-stained whole-slide biopsy and cytology images into predictive biomarkers of cancer therapy response by quantifying cell cycle deregulation and tumor immune microenvironment dynamics. The company sells its breast-cancer-specific 4D QPOR Breast product (FDA Breakthrough Device Designation) and develops customized treatment prediction signatures in partnership with biopharmaceutical companies, clinical research organizations, and academic cancer centers.
Is 4D Path a public or private company?
4D Path is a private company. It is classified as venture growth investor backed and is currently operating.
When was 4D Path founded?
4D Path was founded in 2016. It employs 11 to 50 people.
Where is 4D Path based?
4D Path is headquartered in Belmont, United States, in the North America region.
How does 4D Path make money?
Four revenue lines are on record. Biopharma biomarker discovery and development partnerships are the primary driver. The others are clinical trial biomarker analytics, strategic financing rounds (capital raises) and platform distribution via PathPresenter ClinPx.
Who are 4D Path's main competitors?
Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics, Owkin and Proscia. Broad incumbents are SOPHiA GENETICS, Tempus Labs, Roche (Ventana Digital Pathology) and Philips Digital Pathology. Strata Oncology is listed as an emerging player.
Does 4D Path have an API?
No public API is recorded for 4D Path.
What industry is 4D Path in?
4D Path's product category is Computational Pathology & Predictive Oncology Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 541714 and its SIC code is 8071.